Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie HIV/AIDS Groups Protest Coverage Delays For Hepatitis B Tests

This article was originally published in PharmAsia News

Executive Summary

HIV/AIDS groups in Australia accuse the federal government of unnecessarily delaying for at least six years approval of coverage for a diagnostic for hepatitis B. The government relies on its Medical Services Advisory Committee to recommend federal funding for medical procedures based on their safety and effectiveness. Recently the HIV/AIDS and other groups have complained about the panel's lack of accountability for its approvals process. The HIV/AIDS groups noted it took three years to approve a procedure for determining a patient's hepatitis B viral load because the panel lost paperwork. (Click here for more

You may also be interested in...



MDSAP And USMCA: 3 Ways Mexico Can To Come Up-To-Speed With The Single-Audit Program Targeted By New Free-Trade Accord

The US-Mexico-Canada (USMCA) treaty calls for the three countries to “recognize audits” performed under the Medical Device Single Audit Program. MDSAP is already used by device makers in the US and Canada so they can undergo one audit by an accredited third party to satisfy quality regulations. That leaves Mexico as the odd country out when it comes to using the popular program – and that means it has some catching up to do after the USMCA is ratified by all three nations. Former longtime FDA official Kim Trautman weighs in on how Mexico can incorporate MDSAP into its regulatory framework.

Execs On The Move: Major Changes At Foundation Medicine, Bardy And Lantheus

Genomic profiling firm Foundation Medicine hires new chief commercial officer; Bardy Diagnostics, developer of cardiac arrhythmia devices, picks a chief operating officer; Lantheus Medical Imaging, producer of diagnostic imaging agents and products; brings aboard a new chief medical officer; and more.

Coronavirus: Can Companies Achieve Vaccine Ambition?

UsernamePublicRestriction

Register

SC072443

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel